---
title: "HUTCHMED’s Fanregratinib Delivers Strong Phase II Data in FGFR2-Positive Cholangiocarcinoma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290754777.md"
description: "HUTCHMED reported strong Phase II data for fanregratinib in FGFR2-positive cholangiocarcinoma, showing a 42.5% response rate. China's NMPA granted priority review to its New Drug Application. Approval could strengthen HUTCHMED's oncology portfolio. The stock currently holds a 'Hold' rating with a HK$21.30 target."
datetime: "2026-06-25T00:07:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290754777.md)
  - [en](https://longbridge.com/en/news/290754777.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290754777.md)
---

# HUTCHMED’s Fanregratinib Delivers Strong Phase II Data in FGFR2-Positive Cholangiocarcinoma

HUTCHMED (China) ( (HK:0013) ) has shared an update.

HUTCHMED reported pivotal Phase II data for its FGFR1/2/3 inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, showing an independent review objective response rate of 42.5% and a disease control rate of 83.9%. The single-arm China-based trial also delivered a median duration of response of 6.9 months, progression-free survival of 6.9 months and overall survival of 16.6 months, with rapid onset of action and a manageable safety profile marked mainly by elevated liver enzymes and palmar-plantar erythrodysesthesia.

Supported by these data, China’s National Medical Products Administration has accepted and granted priority review to a New Drug Application for fanregratinib in previously treated advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements. If approved, fanregratinib could become an important targeted option for a hard-to-treat biliary tract cancer segment, strengthening HUTCHMED’s oncology portfolio and reinforcing its position in the fast-growing market for precision cancer therapies in China.

The most recent analyst rating on (HK:0013) stock is a Hold  
with a HK$21.30 price target.  
To see the full list of analyst forecasts on HUTCHMED (China) stock,  
see the HK:0013 Stock Forecast page.

**More about HUTCHMED (China)**

HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It develops drug candidates in-house and has three medicines marketed in China, with its first product also approved in major global markets including the US, Europe and Japan.

**Average Trading Volume:** 4,605,110

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$13.83B

Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)

## Related News & Research

- [HUTCHMED says Phase II fanregratinib trial in FGFR2-altered bile duct cancer posts 42.5% response rate](https://longbridge.com/en/news/290751439.md)
- [15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China](https://longbridge.com/en/news/290470403.md)
- [Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancers](https://longbridge.com/en/news/290619996.md)
- [Everest Medicines enters China commercialization collaboration with Hainan Herui for budesonide enteric capsules](https://longbridge.com/en/news/290642767.md)
- [Gold Stocks Investors Are Buying For Lower Costs And Stronger Balance Sheets](https://longbridge.com/en/news/290636852.md)